Approved Wire coverage, newest first. Market moves and thesis evidence remain separate.
US annual inflation eased to 3.4% in July as food-price growth slowed, while housing continued to keep overall prices elevated. The softer reading reduces near-term inflation pressure, but housing leaves the path for monetary-policy easing less clear.
BioMar raised its 2026 revenue guidance to DKK 17-18 billion from DKK 16-17 billion and EBIT guidance to DKK 1,200-1,300 million from DKK 1,100-1,200 million. The upgrade is clearly positive for BioMar, but with no ticker, consensus, valuation, or price-reaction data supplied, the trade read is limited to the guidance reset.
A benign Consumer Price Index reading would reduce pressure on officials to raise borrowing costs at the September meeting, while a hotter report could revive the case for tighter policy. The setup leaves rate-sensitive assets driven by the inflation surprise rather than by a clear directional signal in advance.
AstraZeneca’s potential $400bn agreement unravelled after investors mounted opposition, according to the Financial Times. The revolt puts deal execution and capital-allocation risk at the center of the AZN setup, even as the company’s latest enrichment shows $58.7B of revenue growing 8.6% YoY.
Oil prices touched $90 a barrel as the U.S.-Iran stalemate hardened and commercial shipping through the Strait of Hormuz continued to dwindle. The setup is bullish for crude-linked producers but raises supply-chain and demand risks for fuel-sensitive industries, with the next read coming from developments around the strait and the conflict.
Silexion Therapeutics priced a $2.5 million public offering of 3,846,161 ordinary shares or equivalents with accompanying Series E warrants at $0.65 per share. The financing extends a clinical-stage RNAi developer’s runway but puts fresh dilution and a deeply negative earnings profile directly in focus.
Cavvy Energy reported an 87% year-over-year increase in NOI, $39 million of debt repayment and higher 2026 guidance, helped by record sulphur revenues. The update strengthens the operating and balance-sheet setup, but the sparse disclosure leaves commodity exposure and the durability of the sulphur contribution as the key second-order risks.
Energy Vault reportedly doubled its backlog and said AI-related wins are accelerating in its Q2 2026 slides. The growth signal is strong, but the latest enrichment still shows a -50.9% net margin and $-0.65 diluted EPS, leaving execution and profitability as the key setup.
The SEC has cleared the JFB-XTEND merger, with closing scheduled for September 1. The approval removes a regulatory hurdle, but JFB’s negative net margin and $-0.31 diluted EPS leave execution and post-close economics as the key risks.
CI&T fell after reporting a Q2 2026 profit miss, even as it raised its outlook. The setup is mixed: improved forward guidance is offset by near-term earnings execution pressure and a low 5.9% net margin.
Super Micro’s latest forecast is exceeding expectations after the company signaled an improved profitability trajectory, sending the stock higher. The setup shifts toward execution risk: strong growth is now paired with thin reported margins, leaving less room for a miss in the next earnings cycle.
Lumentum reported blowout earnings and forecast sales more than doubling as AI demand swells, but the stock was largely flat after hours. The setup is a strong demand read against a valuation and execution burden, with the muted reaction raising the bar for further upside.
CME is partnering with Silicon Data to launch two AI compute futures contracts on Oct. 5, pending regulatory review. The move could broaden CME’s product reach into AI infrastructure, but the contracts’ commercial impact remains unquantified and approval is still outstanding.
Health insurers are withdrawing Medicare Advantage plans, potentially forcing seniors—especially in rural areas with fewer alternatives—to find new coverage next year. The retrenchment highlights regulatory and utilization-cost pressure across UNH, HUM and CVS, but the available data does not identify which company is exiting or quantify the earnings impact.
AppLovin shares fell after Bank of America downgraded the stock, adding a fresh negative catalyst to an otherwise strong operating profile. With revenue of $5.5B growing 70.0% year over year and 60.8% net margins, the setup is a valuation-and-expectations reset rather than an operating deterioration story on the supplied facts.